Transforming Prenatal Care
Through AI-Powered Genomics
EabhaSeq delivers ultra-sensitive genetic screening at 6-7 weeks of pregnancy and generates unlimited synthetic cfDNA data for global genomics research.
Earlier Detection
Reliable testing from 6-7 weeks gestation. Detects conditions at 1-2% foetal fraction vs industry standard 4%+.
Higher Accuracy
50-70% reduction in test failures. Population-specific optimisation for equitable results. AI analysis across 50+ genetic conditions.
Global Impact
Platform-agnostic — works with existing lab systems. Open-source synthetic data tools for research. Eliminates algorithmic bias.
Our Platform
Two Products, One Mission
AI-Enhanced Prenatal Testing
The Clinical Platform
- Ultra-low foetal fraction analysis (1-2%)
- 50+ condition screening in a single test
- Population-specific risk assessment
- Real-time quality assessment and confidence scoring
Synthetic cfDNA Data Generation
Ship Today
- Generate millions of samples across any condition
- Perfect ground truth labelling
- Privacy-preserving alternative to patient data
- 4-level clinical validation framework
The Process
How It Works
Sample Collection
Standard maternal blood draw using existing laboratory protocols
AI Analysis
Foundation model processes cfDNA fragments with population-specific optimisation
Comprehensive Results
Detailed genetic screening with confidence scores and clinical recommendations
Ready to Transform Prenatal Care?
Whether you are a healthcare provider seeking enhanced diagnostic capabilities or a researcher needing high-quality synthetic genomic data, we are accepting partnership and collaboration enquiries.